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Abstract. Relatively little data on secondary cancers is available regarding patients treated for 
non-Hodgkin lymphoma (NHL), compared with those treated for Hodgkin lymphoma. Evolving 
treatment  regimens  have  improved  survival  outcomes  for  NHL  patients.  As  a  result 
improvement, secondary malignancies are becoming an important issue in NHL survivors. This 
review aims to report data on this topic previously published by our group, adding unpublished 
results  from  the  Modena  Cancer  Registry  (MCR).  We  recently  per
secondary neoplasms in NHL survivors: two studies analysing the risk of secondary neoplasms in 
patients treated for indolent and aggressive NHL; a meta
risk of secondary malignant neoplasm 
evaluating the incidence of therapy
(from the MCR database). The first two studies analysed 563 patients with indolent NHL and 1280 
patients  with  diffuse  large  B-cell  lymphoma  (DLBCL)  enrolled  in  the  Gruppo  Italiano  Studio 
Linfomi (GISL) trials. Results showed that the cumulative incidence of secondary tumours was 
10.5% at 12 years for indolent NHL and 8.2% at 15 years for DLBCL. Results of t
indicated that NHL patients experienced a 1.88
general population; the standardized incidence risk (SIR) for secondary acute myeloid leukaemia 
(AML) was 11.07. Based on data from the MCR from 2
was 1.63 for developing a secondary malignancy after NHL, and 1.99 for developing secondary 
haematological malignancies. Regarding myelodysplastic syndrome and/or AML incidence, nine 
NHL patients developed t-MN with 
conclusion, patients treated for NHL are at increased risk of developing SMN. Regarding t
data from the meta-analysis and the MCR demonstrate an excessive risk of developing AML (SIR 
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Relatively little data on secondary cancers is available regarding patients treated for 
Hodgkin lymphoma (NHL), compared with those treated for Hodgkin lymphoma. Evolving 
treatment  regimens  have  improved  survival  outcomes  for  NHL  patients.  As  a  result 
improvement, secondary malignancies are becoming an important issue in NHL survivors. This 
review aims to report data on this topic previously published by our group, adding unpublished 
results  from  the  Modena  Cancer  Registry  (MCR).  We  recently  performed  four  studies  about 
secondary neoplasms in NHL survivors: two studies analysing the risk of secondary neoplasms in 
patients treated for indolent and aggressive NHL; a meta-analysis of 23 studies investigating the 
risk of secondary malignant neoplasm (SMN) after NHL treatment; and a still
evaluating the incidence of therapy-related myeloid neoplasm (t-MN) in patients treated for NHL 
(from the MCR database). The first two studies analysed 563 patients with indolent NHL and 1280 
cell  lymphoma  (DLBCL)  enrolled  in  the  Gruppo  Italiano  Studio 
Linfomi (GISL) trials. Results showed that the cumulative incidence of secondary tumours was 
10.5% at 12 years for indolent NHL and 8.2% at 15 years for DLBCL. Results of t
indicated that NHL patients experienced a 1.88-fold increased risk for SMN compared with the 
general population; the standardized incidence risk (SIR) for secondary acute myeloid leukaemia 
(AML) was 11.07. Based on data from the MCR from 2000 through 2008, we found that the SIR 
was 1.63 for developing a secondary malignancy after NHL, and 1.99 for developing secondary 
haematological malignancies. Regarding myelodysplastic syndrome and/or AML incidence, nine 
MN with a higher risk than expected (SIR 8.8, 95% CI: 4.0
conclusion, patients treated for NHL are at increased risk of developing SMN. Regarding t
analysis and the MCR demonstrate an excessive risk of developing AML (SIR 
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Relatively little data on secondary cancers is available regarding patients treated for 
Hodgkin lymphoma (NHL), compared with those treated for Hodgkin lymphoma. Evolving 
treatment  regimens  have  improved  survival  outcomes  for  NHL  patients.  As  a  result  of  this 
improvement, secondary malignancies are becoming an important issue in NHL survivors. This 
review aims to report data on this topic previously published by our group, adding unpublished 
formed  four  studies  about 
secondary neoplasms in NHL survivors: two studies analysing the risk of secondary neoplasms in 
analysis of 23 studies investigating the 
(SMN) after NHL treatment; and a still-unpublished study 
MN) in patients treated for NHL 
(from the MCR database). The first two studies analysed 563 patients with indolent NHL and 1280 
cell  lymphoma  (DLBCL)  enrolled  in  the  Gruppo  Italiano  Studio 
Linfomi (GISL) trials. Results showed that the cumulative incidence of secondary tumours was 
10.5% at 12 years for indolent NHL and 8.2% at 15 years for DLBCL. Results of the meta-analysis 
fold increased risk for SMN compared with the 
general population; the standardized incidence risk (SIR) for secondary acute myeloid leukaemia 
000 through 2008, we found that the SIR 
was 1.63 for developing a secondary malignancy after NHL, and 1.99 for developing secondary 
haematological malignancies. Regarding myelodysplastic syndrome and/or AML incidence, nine 
a higher risk than expected (SIR 8.8, 95% CI: 4.016.6). In 
conclusion, patients treated for NHL are at increased risk of developing SMN. Regarding t-MN, 
analysis and the MCR demonstrate an excessive risk of developing AML (SIR Mediterr J Hematol Infect Dis 2011; 3; Open Journal System 
11.07 and 5.7, respectively) compared with solid SMN after treatment for NHL. Thus long-term 
monitoring should be considered for NHL survivors.
Introduction. Improved  survival  outcomes  for  non-
Hodgkin lymphoma (NHL) patients, particularly due to 
the  introduction  of  monoclonal  antibodies
1-4 in 
combination with chemotherapy, have raised the issue 
of late treatment sequelae such as secondary tumours. 
Several
5-10 but  not  all
11-13 studies  have  reported  an 
increased risk of developing secondary cancers in NHL 
survivors;  however, few  publications  contain clinical 
characteristics  and  therapy  data  that  are  useful  for 
identifying  risk  factors  for  the  development  of 
secondary  malignancies  related  to  lymphoma 
treatment.  This  lack  is  partly  because  many  studies 
have  analysed  data  from  population-based  registries, 
which  usually  do  not  provide  information  about 
histology subset or therapeutic approaches.
6,7,9-11
In  this  review,  which  includes  some  unpublished 
results based on data from the Modena Cancer Registry 
(MCR), we focus on therapy-related cancers, including
myeloid neoplasms, observed in NHL patients enrolled 
in  the  Gruppo Italiano Studio Linfomi  (GISL) trials, 
and a meta-analysis that we performed on 23 studies 
published on this topic.
14
In  two  previously  published  studies,  our  group 
analysed  two  homogeneous  groups  of  patients  with 
indolent
15 and  aggressive
16 NHL  treated  at  GISL 
centres to determine the incidence rate and risk factors 
for secondary  cancers,  particularly  therapy-related 
myelodysplastic  syndromes/acute  myeloid  leukemia 
(MDS/AML). In addition, we have recently performed 
a  meta-analysis  to  estimate  the  pooled  relative  risk 
(RR) of secondary malignant neoplasm (SMN) in NHL 
survivors
14 and  the  association  between 
chemotherapeutic  or  radiotherapeutic  approaches  and 
site-specific  cancers, focusing our  attention on  MDS 
and AML. Finally, we compared meta-analysis results 
with those obtained from MCR data. This publication 
aims to provide a broad overview of incidence and risk 
factors  for  therapy-related  secondary  neoplasia,  a 
condition that is frequently addressed, but never deeply 
analysed with specific investigations.
Design  and  Methods.  Data  regarding  secondary 
malignancies  in  patients  with  indolent  lymphoma 
(follicular,  marginal  zone,  and  small  lymphocytic 
lymphomas)
15 or aggressive lymphoma (diffuse large 
B-cell lymphoma, DLBCL)
16 treated between 1988 and 
2003  have  been  extracted  from  the  GISL  database, 
located in  Modena, Italy. The  GISL registry collects 
clinical  information  and  treatment  schedules  of  all 
GISL  clinical  trials  from  enrolment  to  follow-up. 
Information is  updated every 36 months during the 
study period, and every 12 months during the follow-
up. The inclusion criteria and statistical method used 
are  reported  in  the  original  papers.
15,16 Among  625 
indolent  lymphomas  enrolled  in  several  clinical 
trials,
17-23 we identified a total of 563 patients who met 
all inclusion criteria. In the second study, 1280 patients 
among  1387  cases  with  DLBCL  were  selected  and 
evaluated for secondary neoplasm. The main goals of 
our studies were to determine the percentage of SMN 
in our cohort, the standardized incidence ratio (SIR), 
and the risk factors for developing secondary cancer in 
lymphoma-treated survivors.
The  meta-analysis
14 was  performed  by  reviewing 
papers  about  secondary  neoplasia  selected  from 
electronic databases (Medline and Embase) to provide 
a global quantitative assessment of the risk for SMN. 
Search strategy, selection criteria, data extraction, and 
statistical  analysis  are  extensively  described  in  the 
original article. Every effort to avoid selection bias was 
adopted. A total of 1,521 citations were identified from 
the electronic search; at the end of selection, 23 papers 
satisfied all inclusion criteria.
The  unpublished  results  that  we  describe  herein 
come  from  the  MCR  database.  The  analysis  was 
addressed  to  the  identification  of  secondary  cancer 
after  primary  neoplasm,  particularly  after  NHL, 
diagnosed  between  2000  and  2008.  Data  from  the 
MCR allows us to evaluate incidence and RR of SMN, 
and particularly of therapy-related myeloid neoplasms 
(t-MN),  from  a  database  population  registry.  These 
data  reflect  clinical  practice  in  a  well-defined  time 
period and geographical area.
Results. 
Clinical trial results. In the study on secondary cancer 
after  indolent  lymphoma,
15 39  patients  out  of  563 
(6.9%) developed an SMN after a median follow-up of 
62 months. We observed 12 MDS/AML cases, with a 
median time between the diagnosis of lymphoma and t-
MN of 25 months (range 6168 months), highlighting 
the onset of myeloid neoplasm within 23 years after 
the first tumour. We also identified 27 solid cancers, 
with  a  median  time  from  diagnosis  of  NHL  to 
diagnosis  of  SMN  of  52  months  (range  16164 
months).  In  the  study  population,  the  risk  of  a 
secondary  tumour  was  higher  (SIR  1.9,  95%  CI: 
1.42.7)  than  the  risk  of  malignancy  in  the  general 
Italian  population,  particularly  among  male  patients 
(SIR  2.72;  95%  CI:  1.764.02,  p=0.016)  and  in 
patients  younger  than  65  years  (SIR  2.66;  95%  CI: 
1.694.0, p=0.037) (Table 1). In particular, SIR wasMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1.  Standardized  Incidence  Risk  (SIR)  according  to 
demographics and treatment in indolent lymphoma survivors.
Factor SIR (95%CI) p value
Overall SIR 1.9 (1.4-2.7)
Gender
F 1.10 (0.50-2.10) 0.016
M 2.72 (1.76-4.02)
Age at first treatment
<65 2.66 (1.69-4.00) 0.037
65+ 1.26 (0.63-2.26)
Histology
FL 2.58 (1.58-3.98) 0.251
SLL 1.49 (0.80-2.55)
MZL 1.15 (0.03-6.43)
RT-IF
No 1.88 (1.25-2.71) >0.5
Yes 2.48 (0.91-5.40)
Chemotherapy containing
Alk 1.54 (0.74-2.83) 0.074
Alk+Anthra  1.57 (0.78-2.80)
Alk+Anthra+Fluda 3.41 (1.81-5.83)
FL:  follicular  lymphoma;  SLL:  small  lymphocytic  lymphoma; 
MZL:  marginal  zone  lymphoma;  Alk:  alkylating  agent;  Anthra: 
anthracycline; Fluda: fludarabine.
4.91  (95%  CI:  2.210.1)  in  the  cohort  groups  aged 
4554 years, and 3.41 (95% CI: 1.985.87) in those 
aged 5564 years. Regarding treatment, we observed 
an  increased  risk  for  each  schedule  of  therapy.  In 
particular,  fludarabine-containing  regimens  were 
associated with a higher risk of developing a secondary 
neoplasm (SIR 3.41; 95% CI: 1.815.83). It should be 
noted that we calculated the overall SIR of secondary 
malignancies  excluding  MDS/AML  cases,  as  the 
incidence rates of these malignancies are not reported 
by  the  Italian  Institute  of  Health.  In  univariate  and 
multivariate analysis, age, male sex, and fludarabine-
based  treatment  each  had a  negative impact on time 
free from secondary tumours.
In  our  second  study,  which  focused  on  the 
evaluation of SMN after DLBCL
16 in patients treated in 
GISL trials,
24-34 48 patients (3.8%, crude rate 7.6 per 
1000  person-years)  out  of  1280  developed  a  second 
cancer. Of these 48 patients with secondary cancers, 
eight  developed  MDS  (n=5)  or  AML  (n=3),  five 
developed other haematological malignancies, and 35 
developed solid tumours. Fourteen out of 48 secondary 
malignancies  occurred  after  additional  treatments  for 
progressive  or  recurrent  disease.  The  median  time 
between the diagnosis of DLBCL and secondary solid 
tumour  diagnosis  was  71  months  (range,  13176
Table  2. Standardized  Incidence  Risk  (SIR)  according  to 
demographics and treatment in DLBCL survivors.
Factor SIR (95%CI) p value
Overall SIR 1.1(0.8-1.5)
Gender
F 1.00 (0.57-1.62) 0.618
M 2.72 (1.76-4.02)
IPI
0-1 1.13 (0.69-1.75) 0.959
02-mag 1.15 (0.71-1.76)
Chemotherapy
PCB-epidoxorubicin 1.22 (0.78-1.81) 0.610
PCB-idarubicin 1.12 (0.45-2.31)
PCB-sequential 1.24 (0.46-2.70)
CHOP or CHOP like 0.60 (0.16-1.55)
RT-IF
No 1.16 (0.79-1.63) 0.549
Yes 0.92 (0.42-1.75)
Cohort Age
20-39 23.0 (5.76-92.0)
40-59 4.39 (1.92-1.78)
PCB-epidoxorubicin:  ProMECE-CytaBOM:  (methylprednisolone, 
cyclophosphamide,  epidoxorubicin  -or  doxorubicin-,  etoposide, 
cytarabine,  bleomycin,  vincristine,  methotrexate);  PCB-idarubicin: 
ProMICE-CytaBOM  (methylprednisolone,  cyclophosphamide, 
idarubicin,  etoposide,  cytarabine,  bleomycin,  vincristine, 
methotrexate); PCB-Sequential: sequential ProMECE instead of the 
classical cycling regimen; CHOP: cyclophosphamide, doxorubicin 
vincristine, prednisolone. RT-IF: radiotherapy-involved field.
months);  for  patients  who  developed  secondary 
MDS/AML,  the  median  time  between  diagnosis  of 
DLBCL  and  t-MN  was  43  months  (range  30127 
months). In contrast to patients with indolent NHL, the 
overall  risk  of  secondary  cancer in  patients  with 
DLBCL  was  similar  to  that  observed  in  the  general 
Italian population (SIR 1.1; 95% CI: 0.81.5) (Table 
2). We did not calculate the SIR of MDS/AML, as the 
incidence rates of these malignancies are not reported 
by  the  Italian  Institute  of  Health.  Sex,  international 
prognostic  index  score,  chemotherapy  regimens, 
radiotherapy, number of chemotherapy lines, and time 
of first treatment did not have any significant impact 
on  the  SIR  of  developing  a  secondary  cancer. 
However, an increased and statistically significant risk 
of SMN was observed in the cohort groups of 2039 
years  and  4059  years  of  age.  The  cumulative 
incidence of SMN after correction in a competing-risk 
model  was  2.3%,  4.7%,  and  8.2%  at  5,  10,  and  15 
years,  respectively.  Considered separately,  the 
cumulative incidence  at  the same time  intervals  was 
1.5, 3.3, and 6.8 for solid tumours, and 0.8, 1.4, and 1.4 Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. Forest plot of the meta-analysis relating risk for secondary solid tumors in NHL survivors.
for haematological malignancies, respectively. We did 
not observe any plateau in the curve of diagnosis of 
secondary  solid  tumours,  while  the  curve  of 
haematological  malignancies  stopped increasing  after 
10 years. The only factor that had a significant negative 
impact on the development of secondary tumours was 
age  >60  years  at  first  treatment;  no  other  factor 
appeared to significantly influence the development of 
SMN. In a separate analysis, no variable appeared to be 
associated with the development of MDS/AML.
Meta-analysis  results.  For  the  meta-analysis,
14 we 
initially  identified  1,521  potentially  eligible  studies. 
Based  on  the  inclusion  criteria,  23  papers  were 
analysed; of these, 21 studies contributed to principal 
meta-analysis on the risk of developing SMN, and 19 
provided risk factors for specific cancer types. For the 
evaluation  of  overall  secondary  malignancy  risk,  we 
analysed  23  studies  that  included  a  total  of  208,643 
NHL survivors who developed 13,878 SMN recruited 
during the period 19352004. The pooled RR of SMN 
was  1.88  (95%  CI:  1.582.22),  an  increased, 
statistically  significant  value  in  comparison  with  the 
risk  of  the  general  population  (Figure  1).  When 
separately calculated, the pooled RRs for clinical trials, 
hospital-based  studies,  and  population-based  studies 
were 2.36, 2.11, and 1.27, respectively. To evaluate the 
risk of secondary AML, 19 studies including a total of 
197,456  NHL  survivors  recruited  during  the  period 
19352004  were  reviewed.  The  calculated  RR  for 
AML  in  this  population  was  11.07  (95%  CI: 
4.6726.26) (Figure 2). For all studies, meta-analysis 
revealed  a  significant  association  between  previous 
NHL  and  the  risk  of  developing  secondary  solid 
cancers with a RR of 1.32 (95% CI: 1.07–1.63), which 
was  extremely  different  from  the  RR  for  AML. 
Younger  age  and  exposure  to  total  body  irradiation 
were significantly associated with an increased risk of 
developing a secondary tumour.
The  use  of  any  type  of  chemotherapy  alone  was 
associated with a higher risk of developing a SMN. A 
similar  result  was  observed  in  the  sub-analysis  of 
patients treated with alkylating agents only; while the 
pooled RR of SMN for patients that received treatment 
with  cyclophosphamide,  adriamycin,  vincristine,  and 
prednisone  (CHOP)  or  CHOP-like  therapy  or 
radiotherapy alone was increased, but not to the point 
of  statistical  significance.  The  combination  of 
chemotherapy  and  radiotherapy  was  significantly 
associated with an increased risk of overall SMN, but 
not of solid tumours.
Modena Cancer Registry results. From the review of 
the MCR database between 1990 and 2008, we found 
332  cases  with  double  diagnoses  of  myeloid 
malignancies associated with any other type of tumour. 
Of  these,  148  were  chronic  myeloproliferative 
disorders  and  were  excluded  from  the  analysis.  The 
remaining  184  cases  had  a  diagnosis  of 
leukemia/MDS;  of  these,  51  were  MDS  diagnosed
NOTE: Weights are from random effects analysis
.
.
.
Overall  (I-squared = 97.5%, p = 0.000)
(reference)
André et al. 2004 M (17)
Clinical trials
Subtotal  (I-squared = 98.8%, p = 0.000)
Leung et al. 2001 (79)
Tward et al. 2006 (19)
Greene & Wilson 1985 (83)
Arcaini et al. 2007 (82)
Takenaka et al. 1985 (75)
Hospital or Specialist centre-based studies
Subtotal  (I-squared = 96.2%, p = 0.000)
Lavey et al. 1990 (76)
Lishner et al. 1991 (77)
André et al. 2004 F (17)
Sacchi et al. 2008 (74)
Travis et al. 1996 (23)
Brown et al. 2005 (27)
Iannitto et al. 2006 (81)
Guadagnolo et al. 2006 (80)
Subtotal  (I-squared = 97.1%, p = 0.000)
Tanaka et al. 1997 (78)
Barista et al. 2002 (71)
Sacchi et al. 2008 (73)
Bluhm et al. 2008 (21)
Brennan et al. 2005 (84)
Population-based studies
Mudie et al. 2006 (18)
Study
1.88 (1.58, 2.22)
Relative Risk (95% CI)
0.92 (0.68, 1.25)
1.28 (1.05, 1.56)
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Figure 2. Forest plot of the meta-analysis relating risk for secondary AML in NHL survivors
before  another  cancer  and  133  were  leukemia/MDS
diagnosed  after  other  tumours.  Notably,  more  than 
50% of these 133 cases were diagnosed after breast, 
gastrointestinal, and urothelial cancers.
Like  other  population-based  registries,  the  MCR 
does not record data about clinical features, molecular 
markers, cytogenetics, treatments,  etc. The  collection 
of  these  data  (called  high  resolution  analysis)  is 
actually ongoing in a separate database.
Between 2000 and 2008 in the province of Modena, 
the  SIR  for  SMN  after  NHL  was  1.63  (95%  CI: 
1.441.85), and the SIR for secondary haematological 
neoplasm  was  1.99  (95%  CI:  1.273.12).  In  this 
population, nine NHL patients developed t-MN (SIR 
8.8; 95% CI: 4.016.6); based on these findings, the 
SIR  was  5.7  (95%  CI:  1.216.7)  for  AML,  and  6.7 
(95% CI: 2.414.5) for MDS.
Conclusions.  Today,  successful  treatments  have 
improved  the  life  expectancy  of  patients  with  NHL, 
and the risk of late treatment effects is becoming an 
important concern. Although the majority of published 
studies have shown that NHL patients are at a greater 
risk of developing secondary malignancies, the results 
of  some  studies  are  conflicting.  In  this  article,  we 
review data from three studies published by our group 
reporting risks of post-treatment secondary neoplasia in 
patients with indolent
15 and aggressive NHL
16 enrolled 
in  GISL  clinical  trials,  and  the  results  of  a  meta-
analysis of 23 publications from 1985 to 2008.
14 We 
also report previously unpublished data from the MCR 
about  the  risk  of  developing  a  secondary  tumour  in 
NHL survivors. While the first two studies evaluate the 
risk in selected patients enrolled in clinical trials, the 
data from the MCR and the meta-analysis refer to risk 
in  a  non-selected  population,  therefore  providing 
findings that more closely resemble clinical practice.
The  two  studies  on  survivors  of  indolent
15 and 
aggressive  NHL
16 analysed  large  and  homogeneous 
cohorts of patients who participated in clinical trials at 
GISL centres for a time period spanning more than 15 
years. Patients’ data were recorded prospectively in the 
GISL  database;  however,  the  results  must  be 
interpreted cautiously  because  of  the  retrospective 
nature of the analysis, that may underestimate the risk 
of secondary cancer.
Looking at the results in patients treated for indolent 
NHL, the overall risk of SMN, excluding MDS/AML, 
appeared  only  slightly  increased  compared  with  the 
risk of malignancy observed in the general population. 
Increased risk  of malignancy  was  observed in  males 
and in patients aged 4564 years; the risk in patients 
older than 65 was equivalent to the risk of cancer in the 
general  population. The  overall  RR  of  secondary 
NOTE: Weights are from random effects analysis
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malignancy  was  increased  for  each  treatment 
combination,  but  was  particularly  elevated  among 
patients treated with fludarabine-based chemotherapy. 
The  possible  role  of  fludarabine  as  a  risk  factor  for 
secondary t-MDS/AML has been recently reported in 
patients treated for chronic lymphocytic leukemia and 
indolent lymphoma.
35 In conclusion, young age at the 
time  of  diagnosis,  male  sex,  and  fludarabine-based 
treatment emerged as negative risk factors for SMN. 
Considered  together  with  conventional  prognostic 
factors and the possible side effects of treatment, these 
data could be a helpful device to support physicians in 
choosing the most appropriate therapy.
In the  cohort  of  patients  treated  for  DLBCL, our 
results  demonstrated  that  the  overall  incidence  of 
secondary  malignancies  was  not  significantly 
increased. However, the risk of developing a secondary 
cancer  was  clearly  age-related  (as  in  survivors  of 
indolent  lymphoma):  a  strongly  increased  risk  was 
observed  in  young  patients,  while  the  incidence  in 
patients  aged  ≥ 60  years  was  equivalent  to  the 
incidence  in  the  general  population.  Clinical 
characteristics,  treatment  regimen,  and  being  treated 
with radiotherapy after chemotherapy did not have any 
influence over the SIR. Use of the new approach of 
involved field radiotherapy or a short follow-up period 
may be possible reasons for these findings.
Our  observations  of  the  cumulative  incidence  of 
secondary  tumours  for  survivors  of  DLBCL  were 
similar to those reported by other  authors. However, 
while we did not observe any plateau in the curve of 
diagnosis  of  secondary  solid  neoplasia  (cumulative 
incidence was still increasing after 1215 years), the 
cumulative  incidence  of  hematologic  malignancies 
stopped increasing after 10 years. A longer follow-up 
is needed to confirm that the risk in our cohort is the 
same  as  that  in  the  normal  population.  Taking  into 
account  the  possible  occurrence  of  secondary 
neoplasia, long-term follow-up should be considered.
The  meta-analysis  was  conducted  to  estimate  the 
risk of SMN for patients with previous NHL in a wide 
population. In this extensive research, we observed that 
NHL survivors have approximately twice the increased 
risk  of  SMN  compared  with  the  general  population. 
Limiting  the  analysis  to  solid  cancers,  we  also 
observed  an  increased  risk  associated  with  younger 
age, as in our previous study of patients with NHL. The 
possible  association  between  treatment  exposure  and 
SMN risk was not explored in detail because treatment 
information was limited for some studies. In any case, 
we observed that the increased risk of secondary cancer 
was  related  to  the  degree  of  exposure  to  alkylating 
agents, alone or in combination with radiotherapy. A 
stronger  association  was  observed  for  patients 
undergoing  total  body irradiation,  although  the 
correlation between radiation therapy and SMN has not 
been  completely  clarified.  A  recent  publication 
reported an increased risk of secondary solid tumours, 
but  not  secondary  MDS/AML,  in  patients  receiving 
radiotherapy after high dose treatment for lymphoma.
36
We  know  that  our  meta-analysis  has  specific 
limitations (e.g. lack of data from unpublished studies, 
restriction to English-language publications). However, 
the likelihood of publication bias in our results is small 
and not statistically significant. In addition, there is a 
large degree of variability among the selected papers 
regarding  characteristics  such  as  study  design,  NHL 
histology, year of recruitment, follow-up duration, type 
of  treatment  administered,  and  environmental  and 
genetic influences. In particular, the studies cover an 
extended  period  of  time  (1935–2004)  during  which 
great  changes  occurred  in  therapeutic  regimens, 
resulting  in  a  significant  change  in  responses  to 
therapy.  Strengths  of  this  study  include  the  use  of 
rigorous  systematic  review  and  meta-analysis 
techniques to retrieve and analyse data.
Finally, data from the  MCR demonstrated similar 
results: an increased risk of SMN and t-MN in NHL 
survivors, with comparable results in population-based 
studies and in clinical trials. High-resolution analysis is 
ongoing  to  define  the  clinical  features  and 
chemotherapy in detail.
In  conclusion,  these  results  confirm  that  NHL 
survivors experience a higher risk of developing SMN 
than the general population, and highlight the variety 
of  possible  carcinogenic  effects  of  different 
chemotherapeutic  approaches  and  combined-modality 
therapies, particularly in younger patients. Regarding t-
MN,  data  from  the  meta-analysis  and  the  MCR 
demonstrate  an  excessive  risk  of  developing  AML 
(SIR 11.07 and 5.7, respectively) compared with solid 
SMN  after  treatment  for  NHL.  Certainly,  additional 
analysis  and  longer  follow-up  periods  are  needed  to 
confirm these observations.
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